Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury

International Journal of Experimental Pathology

Volumn 86, Issue 5, 2005, Pages 279-288

  Segel, Michael J ^a,d   Aqeilan, Kami ^b   Zilka, Keren ^b   Lorberboum Galski, Haya ^b   Wallach Dayan, Shulamit B ^a   Conner, Michael W ^c   Christensen, Thomas G ^c   Breuer, Raphael ^a,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Fibrosis; Genetic engineering; Immunotherapy; Interstitial lung disease

Indexed keywords

BLEOMYCIN; CHIMERIC PROTEIN; HYDROXYPROLINE; INTERLEUKIN 2; INTERLEUKIN 2 BAX FUSION PROTEIN; INTERLEUKIN 2 PSEUDOMONAS EXOTOXIN 66 FUSION PROTEIN; INTERLEUKIN 2 RECEPTOR; PROTEIN BAX; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG TARGETING; GENETIC ENGINEERING; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; LYMPHOCYTE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PARAMETER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BACTERIAL TOXINS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; GENETIC ENGINEERING; HYDROXYPROLINE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PULMONARY FIBROSIS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 26244467667     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0959-9673.2005.00436.x     Document Type: Article

References (46)

1. Aqeilan R., Kedar R., Ben-Yehudah A., Lorberboum-Galski H. (2002) Mechanism of action of IL2-Bax: an apoptosis-inducing chimeric protein targeted against interleukin-2 receptor expressing cells. Biochem. J. 30, 332-338.
2. Aqeilan R., Yarkoni S., Lorberboum-Galski H. (1999) Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett. 457, 271-276.
3. Arima N., Kamio M., Imada K. et al. (1992) Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling. J. Exp Med. 176, 1265-1272.
4. Berkman N., Kremer S., Or R. et al. (2001) Human recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury. Respiration 68, 169-177.
5. Brinkmann U. & Pastan I. (1994) Immunotoxins against cancer. Biochim. Biophys. Acta 1198, 27-45.
6. Case J.P., Lorberboum-Galski H., Lafyatis R., FitzGerald D., Wilder R.L., Pastan I. (1989) Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc. Natl Acad. Sci. USA 86, 287-291.
7. Chandler D.B., Hyde D.M., Giri S.N. (1983) Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Pathol 112, 170-177.
8. Ekimoto H., Aikawa M., Ohnuki T. et al. (1985) Immunological involvement in pulmonary fibrosis induced by peplomycin. J. Antibiot (Tokyo) 38, 94-98.
9. Helene M., Lake-Bullock V., Zhu J., Hao H., Cohen D.A., Kaplan A.M. (1999) T cell independence of bleomycin-induced pulmonary fibrosis. J. Leukoc Biol. 65, 187-195.
10. Herbert C.P., de Smet M.D., Roberge F.G. et al. (1991) Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation 52, 470-474.
11. Hesterberg T.W., Gerriets J.E., Reiser K.M., Jackson A.C., Cross C.E., Last J.A. (1981) Bleomycin-induced pulmonary fibrosis: correlation of biochemical, physiological, and histological changes. Toxicol. Appl. Pharmacol. 60, 360-367.
12. Hibbs M.S., Postlethwaite A.E., Mainardi C.L., Seyer J.M., Kang A.H. (1983) Alterations in collagen production in mixed mononuclear leukocyte-fibroblast cultures. J. Exp Med. 157, 47-59.
13. Izbicki G., Or R., Christensen T.G. et al. (2002a) Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L1110-L1116.
14. Izbicki G., Segel M.J., Christensen T.G., Conner M.W., Breuer R. (2002b) Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol. 83, 111-119.
15. Johnson R.L., Ziff M. (1976) Lymphokine stimulation of collagen accumulation. J. Clin. Invest. 58, 240-252.
16. Katzenstein A.L. & Myers J.L. (1998) Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157, 1301-1315.
17. Kozak R.W., Lorberboum-Galski H., Jones L. et al. (1990) IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J. Immunol. 145, 2766-2771.
18. Kremer S., Breuer R., Lossos I.S. et al. (1999) Effect of immunomodulators on bleomycin-induced lung injury. Respiration 66, 455-462.
19. Laxer U., Lossos I.S., Gillis S. et al. (1999) The effect of enoxaparin on bleomycin-induced lung injury in mice. Exp. Lung Res. 25, 531-541.
20. Lazo J.S., Hoyt D.G., Sebti S.M., Pitt B.R. (1990) Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol. Ther. 47, 347-358.
21. Lorberboum-Galski H., Barrett L.V., Kirkman R.L. et al. (1989) Cardiac allograft survival in mice treated with IL-2-PE40. Proc. Natl. Acad. Sci. USA 86, 1008-1012.
22. Lorberboum-Galski H., FitzGerald D., Chaudhary V., Adhya S., Pastan I. (1988a) Cytotoxic activity of an interleukin 2-pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 1922-1926.
23. Lorberboum-Galski H., Garsia R.J., Gately M. et al. (1990) IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. J. Biol. Chem. 265, 16311-16317.
24. Lorberboum-Galski H., Kozak R.W., Waldmann T.A., Bailon P., FitzGerald D.J., Pastan I. (1988b) Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J. Biol. Chem. 263, 18650-18656.
25. Lorberboum-Galski H., Lafyatis R., Case J.P., FitzGerald D., Wilder R.L., Pastan I. (1991) Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int. J. Immunopharmacol. 13, 305-315.
26. Lossos I.S., Izbicki G., Or R., Goldstein R.H., Breuer R. (2000) The effect of suramin on bleomycin-induced lung injury. Life Sci. 67, 2873-2881.
27. Lossos I.S., Or R., Ginzburg V., Christensen T.G., Mashriki Y., Breuer R. (2002) Cyclosporin A upmodulates bleomycin-induced pulmonary fibrosis in BALB/c mice. Respiration 69, 344-349.
28. Ogata M., Lorberboum-Galski H., FitzGerald D., Pastan I. (1988) IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. J. Immunol. 141, 4224-4228.
29. Postlethwaite A.E., Smith G.N., Mainardi C.L., Seyer J.M., Kang A.H. (1984) Lymphocyte modulation of fibroblast function in vitro: stimulation and inhibition of collagen production by different effector molecules. J. Immunol. 132, 2470-2477.
30. Roberge F.G., Lorberboum-Galski H., Le Hoang P. et al. (1989) Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J. Immunol. 143, 3498-3502.
31. Rose J.W., Lorberboum-Galski H., Fitzgerald D. et al. (1991) Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 32, 209-217.
32. Schrier D.J., Phan S.H., McGarry B.M. (1983) The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am. Rev. Respir. Dis. 127, 614-617.
33. Segel M.J., Or R., Tzurel A. et al. (2001) All-trans-retinoic acid (ATRA) is of no benefit in bleomycin-induced lung injury. Pulm Pharmacol. Ther. 14, 403-407.
34. Sharma S.K., MacLean J.A., Pinto C., Kradin R.L. (1996) The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am. J. Respir. Crit. Care Med. 154, 193-200.
35. Snider G.L., Celli B.R., Goldstein R.H., O'Brien J.J., Lucey E.G. (1978) Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied. Am. Rev. Respir. Dis. 117, 289-297.
36. Steinberger I., Ben-Bassat H., Hochberg E., Lorberboum-Galski H. (1997) Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66 (4Glu) to characterize internalization via IL-2 receptor subunits. Scand. J. Immunol. 46, 129-136.
37. Steinberger I., Brenner T., Lorberboum-Galski H. (1995) Interleukin-2 pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients. J. Neurol. Sci. 133, 183-191.
38. Szapiel S.V., Elson N.A., Fulmer J.D., Hunninghake G.W., Crystal R.G. (1979) Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am. Rev. Respir. Dis. 120, 893-899.
39. Taniguchi T. & Minami Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73, 5-8.
40. Thrall R.S. & Barton R.W. (1984) A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis. Am. Rev. Respir. Dis. 129, 279-283.
41. Thrall R.S., Lovely E.J.I., Baron R.W., McCormick J.R., Phan S.H., Ward P.A. (1980) The effect of T cell depletion on the development of bleomycin-induced pulmonary fibrosis in the rat. Am. Rev. Respir. Dis. 121(s), 99.
42. Thrall R.S., McCormick J.R., Jack R.M., Phan S.H., Ward P.A. (1979) The effect of antilymphocyte globulin on the development of bleomycin-induced pulmonary fibrosis in the rat. Am. Rev. Respir. Dis. 119(s), 83.
43. Tzurel A., Segel M.J., Or R., Goldstein R.H., Breuer R. (2002) Halofuginone does not reduce fibrosis in bleomycin-induced lung injury. Life Sci. 71, 1599-1606.
44. Volk H.D., Muller S., Yarkoni S., Diamantstein T., Lorberboum-Galski H. (1994) Mechanisms of dichotomous action of IL-2-pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response. J. Immunol. 153, 2497-2505.
45. Waldmann T.A. (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today 14, 264-270.
46. Zhu J., Cohen D.A., Goud S.N., Kaplan A.M. (1996) Contribution of T lymphocytes to the development of bleomycin-induced pulmonary fibrosis. Ann. N Y Acad. Sci. 796, 194-202.